Navigation Links
BioTech Holdings Announces First Clinical Use of Microbiome Optimized Autologous Stem Cells

SAN DIEGO, July 7, 2017 /PRNewswire/ -- BioTech Holdings announced today clinical safety data on 3 patients suffering from critical limb ischemia treated with the Company's Procell microbiome-optimized personalized stem cell product. 

In the investigator initiated pilot study, patients with diabetes associated circulation deficit in the legs (critical limb ischemia), who failed previous treatments were administered their own bone marrow derived stem cells that were treated with the Company's proprietary microbiome-derived compounds. 

No treatment associated adverse reactions were observed and patients were followed-up for 3 months.  Furthermore, 2 of the 3 patients had documented improvement in leg circulation and healing of previously unhealing ulcers.

"It is well known that the microbiome controls many aspects of human health and disease ranging from obesity, to autoimmunity, to even neurological function," said Thomas E Ichim, Ph.D, President and CEO of Biotech Holdings. "We are fortunate to have filed intellectual property on application of probiotics and microbiome manipulation to stem cells more than a year ago1.  The current study supports our forward movement of our ProCell product to formal clinical trials."

The Company's product, Procell, comprises of bone marrow stem cells from the same patient, that are treated with factors generated by the microbiome of healthy patients. The key ingredient that the company has identified as secreted by the microbiome which augments stem cell activity is already approved by the FDA for other indications. Accordingly, the company believes it is eligible for accelerated FDA registration pathways, including the 505b2 pathway.

The Company intends to develop the indication of critical limb ischemia as its first condition. Patients with this conditions have a major amputation rate as high as 40% at 6 months and a mortality rate of 20% to 25% in the first year after presentation. Critical limb ischemia represents a market of approximately 10 billion dollar per year2.


Thomas E Ichim, Ph.D
President and Chief Executive Officer
BioTech Holdings
9255 Towne Centre Drive, #450
San Diego, CA 92121 
858 353 4303
Twitter: @biotechholdings



To view the original version on PR Newswire, visit:

SOURCE Biotech Holdings
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. Founders of Philadelphia Biotech Enterin Inc. Discover Link Between Upper GI Tract Infections and Parkinsons Disease
2. Kibow Biotech Inc. (Buzz of Bio Winner, 2014) Receives US Patent for Gout/Hyperuricemia Product Formulation Based on Modulation of the Gut Microbiome With Probiotics and Prebiotics
3. Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
4. Greater Gainesville Region Advances as Florida’s Leading Location for Biotech Incubation and Technology Transfer
5. Pathway for Veterans into the Biotech Industry
6. UConn Innovation Fund Provides First Round Funding to Three Biotech Startups
7. Biotech Stocks Under Scanner -- Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology
8. Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma
9. Superior Controls and Banks Integration Group Merge, Creating Industry-Leading Biotech System Integration Company
10. iPath Media and DoyleCreek Strategic Communications Join Forces to Offer New Marketing Services to Pharmaceutical and Biotech Companies
11. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
Post Your Comments:
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... line of medical marijuana products targeting the needs of consumers who are incorporating ... Kindred takes place in Phoenix, Arizona. , As operators of two successful Valley ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... experience providing advanced instruments and applications consulting for microscopy and surface analysis, ... in application consulting, Nanoscience Analytical offers a broad range of contract analysis ...
(Date:10/7/2017)... Mass. , Oct. 6, 2017  The ... work of three scientists, Jacques Dubochet, Joachim ... breakthrough developments in cryo-electron microscopy (cryo-EM) ... technology within the structural biology community. The winners ... Scientists can now routinely produce highly resolved, three-dimensional ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):